Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
U.S. Food and Drug Administration Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia Collaboration with Eli Lilly and Company ...
Source: marketscreener.com